These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 28931515)

  • 1. Gemtuzumab Ozogamicin Makes a Comeback.
    Cancer Discov; 2017 Nov; 7(11):1208. PubMed ID: 28931515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anti-CD33 monoclonal antibody drug conjugate--Gemtuzumab ozogamicin (GO)].
    Usui N
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():215-8. PubMed ID: 25831755
    [No Abstract]   [Full Text] [Related]  

  • 3. Gemtuzumab ozogamicin for acute myeloid leukemia.
    Appelbaum FR; Bernstein ID
    Blood; 2017 Nov; 130(22):2373-2376. PubMed ID: 29021230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.
    Gbadamosi M; Meshinchi S; Lamba JK
    Future Oncol; 2018 Dec; 14(30):3199-3213. PubMed ID: 30039981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.
    Norsworthy KJ; Ko CW; Lee JE; Liu J; John CS; Przepiorka D; Farrell AT; Pazdur R
    Oncologist; 2018 Sep; 23(9):1103-1108. PubMed ID: 29650683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.
    Baron J; Wang ES
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):549-559. PubMed ID: 29787320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.
    Ricart AD
    Clin Cancer Res; 2011 Oct; 17(20):6417-27. PubMed ID: 22003069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia.
    Kell J
    Expert Rev Anticancer Ther; 2016; 16(4):377-82. PubMed ID: 26942450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.
    Olombel G; Guerin E; Guy J; Perrot JY; Dumezy F; de Labarthe A; Bastie JN; Legrand O; Raffoux E; Plesa A; Wagner-Ballon O; Cornet E; Salaun V; Preudhomme C; Thomas X; Pautas C; Chantepie S; Turlure P; Castaigne S; Dombret H; Feuillard J
    Blood; 2016 Apr; 127(17):2157-60. PubMed ID: 26929274
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
    Castaigne S; Pautas C; Terré C; Raffoux E; Bordessoule D; Bastie JN; Legrand O; Thomas X; Turlure P; Reman O; de Revel T; Gastaud L; de Gunzburg N; Contentin N; Henry E; Marolleau JP; Aljijakli A; Rousselot P; Fenaux P; Preudhomme C; Chevret S; Dombret H;
    Lancet; 2012 Apr; 379(9825):1508-16. PubMed ID: 22482940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.
    Stasi R
    Expert Opin Biol Ther; 2008 Apr; 8(4):527-40. PubMed ID: 18352855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
    Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.
    Jen EY; Ko CW; Lee JE; Del Valle PL; Aydanian A; Jewell C; Norsworthy KJ; Przepiorka D; Nie L; Liu J; Sheth CM; Shapiro M; Farrell AT; Pazdur R
    Clin Cancer Res; 2018 Jul; 24(14):3242-3246. PubMed ID: 29476018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin.
    Cowan AJ; Laszlo GS; Estey EH; Walter RB
    Front Biosci (Landmark Ed); 2013 Jun; 18(4):1311-34. PubMed ID: 23747885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent research and future prospects for gemtuzumab ozogamicin: could it make a comeback?
    O'Hear C; Rubnitz JE
    Expert Rev Hematol; 2014 Aug; 7(4):427-9. PubMed ID: 24871925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.
    Hills RK; Castaigne S; Appelbaum FR; Delaunay J; Petersdorf S; Othus M; Estey EH; Dombret H; Chevret S; Ifrah N; Cahn JY; Récher C; Chilton L; Moorman AV; Burnett AK
    Lancet Oncol; 2014 Aug; 15(9):986-96. PubMed ID: 25008258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are immunoconjugates approaching "standard of care" in AML?
    Estey E
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):261-8. PubMed ID: 24309528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
    Lambert JM; Morris CQ
    Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment with gemtuzumab ozogamicin monotherapy in a pediatric patient with resistant relapse of acute myeloid leukemia.
    Unal S; Cakir M; Kuşkonmaz B; Cetin M; Tuncer AM
    Turk J Pediatr; 2009; 51(1):69-71. PubMed ID: 19378895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.